Hypertension in postmenopausal women: Pathophysiology and treatment

High Blood Pressure and Cardiovascular Prevention

Volumn 18, Issue 1, 2011, Pages 13-18

  Leuzzi, Chiara ^a   Modena, Maria Grazia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

estrogen; metabolic syndromes; Postmenopausal hypertension

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ESTROGEN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DIET THERAPY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; OXIDATIVE STRESS; POSTMENOPAUSAL HYPERTENSION; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

FEMALE; HUMANS; HYPERTENSION; MALE; POSTMENOPAUSE; SEX FACTORS;

EID: 79955606216     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11588030-000000000-00000     Document Type: Review

References (47)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9 (Pubitemid 37430168)
2. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3 (Pubitemid 351731743)
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13 (Pubitemid 35472129)
4. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32 (Pubitemid 35463925)
5. Burl VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
6. Messerli F, White WB, Staessen JA. If only cardiologists did properly measure blood pressure: blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 2002; 40: 2201-3 (Pubitemid 36005909)
7. Taddei S,Virdis A, Ghiadoni L, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28: 576-82 (Pubitemid 26327952)
8. Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24: 471-6 (Pubitemid 24246550)
9. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43: 918-23 (Pubitemid 38579888)
10. Nuzzo A, Rossi R, Modena MG. Endothelial dysfunction in postmenopausal women and hypertension. Womens Health 2007; 3 (5): 515-8 (Pubitemid 350055940)
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9 (Pubitemid 23132154)
12. Rossi R, Chiurlia E, Nuzzo A, et al. Flow mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 2004; 44: 1636-40 (Pubitemid 39369796)
13. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60 (Pubitemid 37188333)
14. Benetos A, Thomas F, Safar ME, et al. Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middleaged men and women. J Am Coll Cardiol 2001; 37: 163-8 (Pubitemid 32051733)
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. American Heart Association/ National Heart, Lung, and Blood Institute. Circulation 2005; 112: 2735-52 (Pubitemid 41532612)
16. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-9 (Pubitemid 29230863)
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 258: 2486-97
18. Rossi R, Nuzzo A, Origliani G, et al. Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women. Hypertension 2008 Nov; 52 (5): 865-72
19. Rossi R, Turco V, Origliani G, et al. Type 2 diabetes mellitus is a risk factor for the development of hypertension in postmenopausal women. J Hypertens 2006; 24: 2017-22 (Pubitemid 44371269)
20. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13: 1457-62 (Pubitemid 26015762)
21. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10
22. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000; 102: 42-7 (Pubitemid 30430551)
23. Zanchetti A, Facchetti R, Cesana GC, et al. SIMONA participants. Menopause- related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens 2005 Dec; 23 (12): 2269-76 (Pubitemid 41666757)
24. Casiglia E, Ginocchio G, Tikhonoff V, et al. Blood pressure and metabolic profile after surgical menopause: comparison with fertile and naturallymenopausal women. J Hum Hypertens 2000 Dec; 14 (12): 799-805 (Pubitemid 32015832)
25. Izumi Y, Matsumoto K, Ozawa Y, et al. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens 2007; 20: 1045-50 (Pubitemid 47446166)
26. Krug E, Berga SL. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet Gynecol 2002; 99: 893-7 (Pubitemid 34442410)
27. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995; 15: 821-6
28. Kesteren PJV, Kooistra T, Lansink M, et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029-33 (Pubitemid 28224745)
29. Mortenson LH, Pawloski CM, Kanagy NL, et al. Chronic hypertension produced by infusion of endothelin in rats. Hypertension 1990; 15: 729-33 (Pubitemid 20189449)
30. Duerrschmidt N, Wippich N, GoettschW, et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem BiophysRes Comm 2000; 269: 713-7 (Pubitemid 30440367)
31. Fortepiani LA, Zhang H, Racusen LC, et al. Characterization of an animal model of postmenopausal hypertension in SHR. Hypertension 2003; 41: 640-5 (Pubitemid 36314567)
32. Hall JE, Brands MJ, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10: S258-65 (Pubitemid 29159459)
33. Reckelhoff JF, Zhang H, Srivastava K, et al. Subpressor doses of angiotensin II increases plasma F2-isoprostanes in rats. Hypertension 2000; 35: 476-9 (Pubitemid 30054219)
34. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23
35. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab 2000; 85: 1577-83 (Pubitemid 32289503)
36. Kunes J, Hojna S, Kadlecova M, et al. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res 2004; 53 Suppl. 1: S23-34 (Pubitemid 38612851)
37. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-9 (Pubitemid 27349072)
38. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-1
39. Rapelli A. Hypertension and obesity in menopause. J Hypertens 2002; 20: S26-8
40. Rahmouni K, Correia MLG, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14 (Pubitemid 40066405)
41. Vaz M, JenningsG, Turner A, et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423-9 (Pubitemid 27513415)
42. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115: 1481-501 (Pubitemid 46648385)
43. Maruthur NM,WangNY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER trial. Circulation 2009; 119: 2026-31
44. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003 (Pubitemid 34286536)
45. Targonski PV, Bonetti PO, Pumper GM, et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107: 2805-9 (Pubitemid 36705990)
46. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators: risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33 (Pubitemid 34761611)
47. Dubey RK, Imthurn B, Zacharia LC, et al. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004; 44: 789-95 (Pubitemid 39577398)